Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|October 3, 2008
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]Pascale Cony-Makhoul, Anne Bergeron, Sélim Corm, et al.
Cancer Medicine|September 22, 2021
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?Jim Canet, Pascale Cony-Makhoul, Sébastien Orazio, et al.
British Journal of Haematology|February 22, 2023
Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatmentAurélien Belot, Vincent Camus, Cédric Portugues, et al.
British Journal of Haematology|December 22, 2017
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phasePascale Cony-Makhoul, Martine Gardembas, Valérie Coiteux, et al.
Cancer Medicine|May 1, 2019
Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based studyStéphanie Foulon, Pascale Cony-Makhoul, Agnès Guerci-Bresler, et al.
Leukemia Research|August 3, 2010
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patientsSandrine Hayette, Kaddour Chabane, Mauricette Michallet, et al.
British Journal of Haematology|October 3, 2002
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Christophe Barthe, Marie-Josée Gharbi, Valérie Lagarde, et al.
Plos One|September 10, 2014
Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommendedSarah Huet, Pascale Cony-Makhoul, Maël Heiblig, et al.
British Journal of Haematology|April 11, 2016
Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional studyGabriel Etienne, Francoise Huguet, Agnès Guerci-Bresler, et al.
American Journal of Hematology|September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 studyPhilippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
Pageof 6